SAMYA ISMAIL: Open Payments
NPI 1801498084 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,264 in 53 payments from 13 companies in 2025. Trend: 2023 $1,173 · 2024 $765 · 2025 $1,264
Food & beverage: $1,264
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $363 |
| ARS Pharmaceuticals Operations, Inc. | 14 | $232 |
| BioCryst US Sales Co., LLC | 11 | $231 |
| Novartis Pharmaceuticals Corporation | 5 | $132 |
| GlaxoSmithKline, LLC. | 3 | $76 |
| AstraZeneca Pharmaceuticals LP | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| CSL Behring | 1 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| ABBVIE INC. | 1 | $25 |
Products named: DUPIXENT, NEFFY, ORLADEYO, NUCALA, FASENRA, Xhance, TAKHZYRO, AYVAKIT.
Industry payments across NY — which companies pay providers there.
